

THE LARNAKA CALL

A long-term future for European action against cancer

The Larnaka Call is issued at a pivotal moment for European health policy. As the European Union nears the end of the current Multiannual Financial Framework and prepares for the 2028–2034 period, it is essential that health remains a core priority, through the continued implementation of Europe's Beating Cancer Plan.

This Call results from a national initiative led by the elected representatives of the Republic of Cyprus, in close consultation with European and national stakeholders. It reflects a shared hope that the forthcoming Presidency of the Council of the European Union can be taken as a moment to renew and strengthen collective action against cancer.

We, the undersigned, note:

1. That the Republic of Cyprus will hold the **Presidency of the Council of the European Union** during the first half of 2026, providing a significant opportunity to advance strategic priorities in public health, notably in cancer prevention, care, and research.
2. That **Europe's Beating Cancer Plan** and the **EU Cancer Mission** represent landmark European initiatives which have significantly advanced cooperation among Member States, improved access to care, and fostered innovation in cancer control.
3. That **preparations are currently underway for the next EU Multiannual Financial Framework (2028–2034)**, with the European Commission expected to publish a proposal in July 2025. In this context, speculation persists regarding potential reallocation of resources to other areas and restructuring of health and research funding under a broader 'Competitiveness Fund' heading. This creates significant uncertainty regarding the future of Europe's Beating Cancer Plan and the EU Cancer Mission. Without a coordinated and explicit signal from the Member States, the continued prioritisation and adequate resourcing of these initiatives cannot be assured.
4. That **sustained political and financial support at European and national levels is instrumental for the fight against cancer across the continent**. Without the **full delivery and ambitious continuation of Europe's Beating Cancer Plan and the EU Cancer Mission**, Europe will fail to meet its goals and the expectations of its citizens and lose on the opportunity of global leadership in the field. This includes advancing the understanding of cancer, preventing and detecting the disease, ensuring patients' equal access to diagnostics, treatment and multidisciplinary care, and safeguarding quality of life for all those affected.

We, the undersigned, recommend:

1. That the Cypriot Presidency of the Council of the European Union in 2026 be used as a platform to **renew the political mandate for pan-European cooperation in cancer policy and research**.
2. That the Cypriot Presidency initiates, in consultation with Member States and relevant stakeholders, the preparation of **Council Conclusions** reaffirming the shared commitment to collaborative action against cancer for the post-2027 period.
3. That the forthcoming **Multiannual Financial Framework (2028–2034)** shall provide for the **continuation and long-term sustainability** of cancer-related programmes launched under the current framework. Appropriate and stable funding should be allocated to ensure the future of key EU-funded initiatives which serve as critical enablers of coordinated European action in cancer prevention, detection, treatment, research, and survivorship.
4. That pan-European cooperation in cancer policy should constantly seek to reduce disparities in cancer control, both between and within countries. This includes equitable access to cancer prevention, early detection, diagnosis, multimodal cancer treatment and multidisciplinary care, including modern oncology centres, high-quality radiotherapy departments and surgery, research, as well as patient-centred survivorship care and rehabilitation.

A. Kyralides
A. Bury
Antoni
Pavlos Paradisiotis

Διονύσιος Δ. Δελής
Stavros
Μαρόσα Σιγγο
Ελευθ. Τολμα
Λουκάς

A. Typhono
Louka Komninos (EKK)
Louka Komninos
V.P. Andrioukantis



Full list of signatories:

Andreas Vyras, Mayor, Municipality of Larnaka
Stella Kyriakides, Former European Commissioner for Health and Food Safety
Giorgos Georgiou MEP, Substitute, Committee on Public Health
Michalis Hadjipantela MEP, Member, Committee on Public Health
Vytenis Andriuskaitis MEP, Member, Committee on Public Health & Former European Commissioner for Health and Food Safety
Eleni Tolma, Member of the EU Cancer Mission Board
Stella Mastora, President, Europa Donna
Andreas Apostolou, Cyprus Member of Parliament
Andreas Pasiourtides, Cyprus Member of Parliament
Irene Polycarpou, European Federation of Organisations for Medical Physics (EFOMP)
Hugo Ricardo Loureiro Soares, Agencia de Investigação Clínica e Inovação Biomédica (AICIB)
Styliana Mirallai, Corporate Development Manager, ILIKOS CG & Academic in Drug Discovery and Development, University of Nicosia
Sarah Collen, European Association of Urology (EAU)
Laura Panagi, Postdoctoral Researcher in Health Psychology, Cyprus University of Technology (CUT)
Nicos Middleton, Cyprus University of Technology
Andreas Charalambous, Professor, Cyprus University of Technology (CUT)
Christos Tsagkaris MD, MPA, MSc, Member, EU Cancer Mission Board
Angelos Kassianos, Cyprus University of Technology (CUT)
Dr Maria Loizou, Clinical Psychologist & Project Manager, DESIPOC (EU4Health)
Sona Ciernikova, Assoc. Prof., Dr., PhD., MPH, National Oncology Institute, Slovakia
Matej Misik, Health Economics Reseracher, HEPII, Masaryk University
Daniela Kállayová, Senior Public Health Officer, Ministry of Health, Slovakia
Paula Proestou, Center For Social Innovation (CSI)
Stella Mastora, President of Europa Donna
Constantina Constantinou, Professor of Molecular Cancer Biology, University of Nicosia Medical School
Constantinos Zamboglou, Medical Director, German Medical Institute
George Kapetanakis, President, Hellenic Cancer Federation (ELLOK)
Panos Ergatoudes, CEO, Bank of Cyprus Oncology Centre
Maria (Miriam) Dalmas, Ministry for Health and Active Ageing, Malta
Christos Ombashis, Commercial Head, C. G. Papaloizou & Alector Pharmaceuticals
Evie Maifoshie, CEO & Managing Director, Innovethos & Mindwell Foundation
Ivan Ratkovic, Policy Officer, Digestive Cancers Europe (DiCE)
Maria Ioannidou, CEO, The Cyprus Anti-Cancer Society
Tina Rossidou, National Manager, PsychoSocial Services, Cyprus Anti-Cancer Society
Pinelopi Constantinou, The Cyprus Anticancer Society
Iro Maria Demetriou, The Cyprus Anti-Cancer Society
Carina Dantas, CEO, SHINE 2Europe
Gilliosa Spurrier-Bernard, Co-Chair of ECO Patient Advisory Committee & Vice-President, Melanoma Patients Network Europe (MPNE) & President Melanome France & Board Member of WECAN
Nicolò Matteo Luca Battisti, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust
Chiara Kuby, Junior Policy Officer, Cancer Patients Europe
Luis Seijo, Co-Chair, Prevention, Early Detection and Screening Network, European Cancer Organisation (ECO) & Chief of Pulmonary Medicine, Clinica Universidad de Navarra
Simon van den Bergh, Epidemiologist
Violet Aroyo, Board Member, Europa Donna Turkey
Christos Poullos MD, MSc, PhD, Pathologist-Education Manager of the European Society of Pathology
Jolanda Sinha, Head of Communications & Public Affairs, Netherlands Comprehensive Cancer Organisation IKNL
Patrizia Carrieri, INSERM, SESSTIM
Eduardo Pisani, CEO, All.can
Ugnė Mickevičiūtė M. D., PhD candidate, National Cancer Center, Vilnius University, Life Sciences Center
Jörg Geisler MD, Interventional Radiologist
Peter Baker, Chief Executive, Global Action on Men’s Health
Mary Coffey, Adjunct Associate Professor
Prof. Dr. Arnold Ganser, Professor Emeritus, Former Director of the Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School
Daniel Kelly, Professor, Cardiff University
Patrice Forget, Professor, University of Aberdeen & Chair, Advocacy Committee, European Pain Federation EFIC
Len De Nys PhD, Vrije Universiteit Brussel
Ebba Hallersjö Hult, Senior Advisor, Stockholm School of Economics, Co-founder & Head of Vision Zero Cancer – Testbed Sweden
Alex Filicevas, Executive Director, World Bladder Cancer Patient Coalition
Ulrich Ronellenfitsch, Professor, University Hospital Halle (Saale), Germany
Wendy Oldenmenger, Associate Professor, Erasmus MC
Denis Onyango, Director of Programmes
Branislav Bystricky, Head of Oncology, FN Trencin, Slovakia
Maria Varela Calvo MD, PhD, Hospital Universitario Central de Asturias
Camille Groos, Member, Pharmacist Chamber in Luxembourg
Loïc Treffel PhD, Researcher and Clinician, Institut Toulousain d’Ostéopathie (ITO) and Health Sciences University (HSU)
Ahmet Cingöz, Asst. Prof., Bezmialem Vakif University
Niall O’Higgins, Professor Emeritus of Surgery, University College Dublin
Kimon Chatzistamatiou, Assistant Professor, Aristotle University of Thessaloniki, Hellenic HPV Society
Stavroula Chante, Macmillan Lead Cancer Nurse, The Royal Wolverhampton NHS Trust
Hüseyin Örün, Vice-Chair, Survivorship and Quality of Life Network, European Cancer Organisation
Pierluigi Fracasso MD, Member of Public Affair Group of United European Gastroenterology
Nicolas Philippou, The Cyprus Association of Cancer Patients and Friends (PASYKAF)
Ivaylo Petrov, Head of Strategic Planning, Healthcare Programs & Policies; Board Member; Bulgarian Joint Cancer Network (BJCN)
Neringa Ciakiene, Director of Lithuanian Cancer Patient Coalition (POLA)
Debra Montague, President, Lung Cancer Europe
Zacharoula Sidiropoulou, Head of Breast Unit, West Lisbon Local Health Unit
Franco Orsi, Oncology Alliance Sub Committee Member, European Society of Cardiovascular and Interventional Radiology
Dociu Petrut, Psycho-oncologist
Fiorita Poulakaki, President, Europa Donna Greece, & Founding President, Build a Bridge Foundation & Vice President, Europa Donna – The European Coalition
Ana Toledo-Chávarri, Consejo Superior De Investigaciones Científicas (CSIC) & Member, EU Cancer Mission Board
Piotr Rutkowski, Polish Oncological Society
Anna Daniela Iacobone, Early Career Affiliate Board Member, International Papillomavirus Society (IPVS)
Irati Rodriguez Matesanz, Oncology Nurse Practitioner, City of Hope, Atlanta (USA), ECN Co-Chair, EONS
Jose M Martin-Moreno, MD, PhD, DrPH, Professor and Chair, University of Valencia, Catedra GIS-FES Madrid, and Fundacion ECO, Spain
Nikolina Dodlek, Research Associate, Cyprus University of Technology
Richard Price, Policy Director, European Cancer Organisation
Joel Plaja, Director, Oncology Policy – Europe and Canada, AstraZeneca
Assia Konsoulova, Bulgarian Joint Cancer Network
Branka Marinovic, President, European Academy of Dermatology & Venereology (EADV)
Richard Robinson, Head of European Policy & Government Affairs, Bristol Myers Squibb

The latest updated list of signatories at europeancancer.org/larnaka-call.

Supporters:

